Free Trial

Artelo Biosciences Q2 2024 Earnings Report

Artelo Biosciences logo
$0.87 -0.01 (-0.91%)
As of 01:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Artelo Biosciences EPS Results

Actual EPS
-$0.75
Consensus EPS
-$0.85
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Announcement Details

Quarter
Q2 2024
Time
TAS

Conference Call Resources

Remove Ads

Artelo Biosciences Earnings Headlines

Artelo Biosciences (ARTL) to Release Earnings on Monday
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Artelo Biosciences announces new data on ART12.11
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL), a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

View Artelo Biosciences Profile

More Earnings Resources from MarketBeat